Here are the DEF 14A proxy statements from Oscar Health, Inc. (OSCR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow OSCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSCR filings page.
Oscar Health, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 4, 2026 to elect eight directors, approve an advisory say‑on‑pay resolution, and ratify PricewaterhouseCoopers as auditor for 2026. Stockholders of record on April 10, 2026 may vote online, by phone, or by mail.
The Board will move to eight members as former chair Jeffery Boyd steps down and independent director Siddhartha Sankaran becomes chair. All three Board committees are 100% independent. The company highlights 41% revenue CAGR from 2023–2025, 2025 revenue of $11.7 billion, and market share rising from 17% to 30%, with 3.4 million members as of February 1, 2026.
Executive pay emphasizes performance-based equity. For 2025, the executive bonus pool was funded at 91% of target, below the 105.9% formulaic outcome. CEO Mark Bertolini received no new equity in 2025, but his employment was extended through at least April 1, 2029, with 2026 RSU and PSU awards tied to relative total stockholder return.